Literature DB >> 25921770

Enhanced function of inhibitory presynaptic cannabinoid CB1 receptors on sympathetic nerves of DOCA-salt hypertensive rats.

Marek Toczek1, Eberhard Schlicker2, Emilia Grzęda1, Barbara Malinowska3.   

Abstract

AIMS: This study was performed to examine whether hypertension affects the sympathetic transmission to resistance vessels of pithed rats via inhibitory presynaptic cannabinoid CB1 receptors and whether endocannabinoids are involved in this response.
MATERIALS AND METHODS: We compared uninephrectomised rats rendered hypertensive by high salt diet and deoxycorticosterone acetate (DOCA) injections with normotensive animals (uninephrectomy only). Experiments were performed on vagotomised and pithed animals. Increases in diastolic blood pressure (DBP) were induced four times (S1-S4) by electrical stimulation or phenylephrine injection. KEY
FINDINGS: Electrical stimulation (0.75Hz, 1ms, 50V, 5 impulses) of the preganglionic sympathetic nerve fibres innervating the blood vessels more strongly increased DBP in normotensive than in DOCA-salt rats. Phenylephrine (0.01μmol/kg) induced similar increases in DBP in both groups. The cannabinoid receptor agonist CP55940 (0.01-1μmol/kg) did not modify the rises in DBP induced by phenylephrine. However, it inhibited the electrically stimulated increases in DBP, more strongly in DOCA-salt than in normotensive animals (maximally by 50 and 30%, respectively). The effect of CP55940 was attenuated by the CB1 antagonist AM251 (3μmol/kg). AM251 enhanced the neurogenic vasopressor response during S4 by itself in hypertensive rats only. URB597 (3μmol/kg), which inhibits degradation of the endocannabinoid anandamide, did not modify the electrically stimulated increases in DBP. SIGNIFICANCE: The function of inhibitory presynaptic CB1 receptors on sympathetic nerves is enhanced in DOCA-salt hypertensive rats. Thus, the CB1 receptor-mediated inhibition of noradrenaline release from the sympathetic nerve fibres innervating the resistance vessels might play a protective role in hypertension.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  11-Deoxycorticosterone acetate (PubChem CID: 3001); AM251 (PubChem CID: 2125); CP55940; CP55940 (PubChem CID: 104895); Cannabinoid receptors; DOCA–salt hypertension; Phenylephrine hydrochloride (PubChem CID: 5284443); Pithed rat; Presynaptic receptors; Prostaglandin F(2α) (PubChem CID: 5282415); URB597 (PubChem CID: 1383884)

Mesh:

Substances:

Year:  2015        PMID: 25921770     DOI: 10.1016/j.lfs.2015.03.022

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

Review 1.  The endocannabinoid system in cardiovascular function: novel insights and clinical implications.

Authors:  Salvador Sierra; Natasha Luquin; Judith Navarro-Otano
Journal:  Clin Auton Res       Date:  2017-12-08       Impact factor: 4.435

Review 2.  From apelin to exercise: emerging therapies for management of hypertension in pregnancy.

Authors:  Jeffrey S Gilbert
Journal:  Hypertens Res       Date:  2017-04-06       Impact factor: 3.872

3.  Chronic inhibition of fatty acid amide hydrolase by URB597 produces differential effects on cardiac performance in normotensive and hypertensive rats.

Authors:  Anna Pędzińska-Betiuk; Jolanta Weresa; Marek Toczek; Marta Baranowska-Kuczko; Irena Kasacka; Ewa Harasim-Symbor; Barbara Malinowska
Journal:  Br J Pharmacol       Date:  2017-05-31       Impact factor: 8.739

4.  Beneficial Changes in Rat Vascular Endocannabinoid System in Primary Hypertension and under Treatment with Chronic Inhibition of Fatty Acid Amide Hydrolase by URB597.

Authors:  Marta Baranowska-Kuczko; Hanna Kozłowska; Monika Kloza; Ewa Harasim-Symbor; Michał Biernacki; Irena Kasacka; Barbara Malinowska
Journal:  Int J Mol Sci       Date:  2021-05-02       Impact factor: 5.923

Review 5.  Cannabinoids in arterial, pulmonary and portal hypertension - mechanisms of action and potential therapeutic significance.

Authors:  Barbara Malinowska; Marek Toczek; Anna Pędzińska-Betiuk; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2018-04-14       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.